Afinitor licensed for pancreatic tumours

Dosing is the same for all current indications: 10mg once daily

Afinitor (everolimus) is now indicated for the treatment of advanced pancreatic neuroendocrine tumours in patients with unresectable or metastatic disease.

In the randomised, double-blind study, RADIANT-3 (n=410), median progression-free survival more than doubled with everolimus compared with placebo (11.0 vs 4.6 months).

Afinitor is also indicated for use in advanced renal cell carcinoma which has progressed during or after VEGF-targeted therapy. In addition, Novartis are launching everolimus as Votubia for the treatment of astrocytoma.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

An empty tablet blister pack.

Ezetimibe supply update

Availability issues have been reported for the lipid-lowering...

Woman holding blister strip of contraceptive pills

Pharmacists across England to initiate oral contraceptives

Pharmacy Contraception Service (PCS) could allow almost...